Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

NCT03602859 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.

NCT NCT03602859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03602859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Lead sponsor
Tesaro, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 11, 2018
Completion date
April 30, 2029
Enrollment
1,400 (actual)
Sites
182

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms, ovarian, fallopian tube and primary peritoneal carcinoma